CureVac Falls into Oversold Zone (CVAC)
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 16 2025
0mins
Source: NASDAQ.COM
CureVac NV Trading Update: On Tuesday, CureVac NV (CVAC) shares reached an RSI of 29.0, indicating they are in oversold territory, with shares trading as low as $4.775.
Market Comparison: The current RSI for the S&P 500 ETF (SPY) is 47.6, suggesting that CVAC's recent selling pressure may be nearing exhaustion, potentially signaling a buying opportunity.
52-Week Performance: CVAC's stock has a 52-week low of $2.475 and a high of $5.72, with the last trade recorded at $4.80.
Author's Disclaimer: The opinions expressed in the article are those of the author and do not necessarily reflect the views of Nasdaq, Inc.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
